Biopharmaceutical News and Research

RSS

Decision Resources announces acquisition of PharmaStrat

Decision Resources Group, one of the world's leading research and advisory firms focusing on healthcare insights and analysis, announced today that it acquired PharmaStrat, the leading consulting and market research services firm focused on issues related to reimbursement and organized customer segments for biopharmaceutical manufacturers.

26 Jul 2011

Mayo Clinic trial to evaluate folate receptor alpha-targeted breast/ovarian cancer vaccine

VaxOnco, a leading oncology biopharmaceutical company, today announced that following FDA IND approval, it will sponsor a Phase I folate receptor alpha-targeted therapeutic vaccine clinical trial in disease-free patients, previously diagnosed with either breast or ovarian cancer at Mayo Clinic.

25 Jul 2011

Galectin, University of Michigan enter collaboration to study role of Galectins in cardiovascular disease

Galectin Therapeutics Inc. today announced that it has entered into a research collaboration with Dr. Jose Jalife of the University of Michigan Medical School to better understand the relationship of Galectin-3 to cardiac fibrosis in chronic cardiac arrhythmias.

21 Jul 2011

Identification of third microRNA target triggers milestone payment from GSK to Regulus

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK.

21 Jul 2011

PAREXEL completes 100th Asian ethnobridging study

PAREXEL International Corporation, a leading global biopharmaceutical services provider, announced today that it has achieved a significant milestone by completing its 100th Asian ethnobridging study, which is designed to help biopharmaceutical companies accelerate development for the Asia/Pacific market.

From Parexel 21 Jul 2011

Malvern and Paraytec enter into development and technology licensing agreement

Malvern Panalytical (Malvern Panalytical, UK) and Paraytec Ltd (York, UK) have entered into a development and licensing agreement that will see Paraytec’s ActiPix® technology being added to Malvern Panalytical’s materials characterization portfolio. The agreement will give Malvern Panalytical exclusive rights to further develop, market and sell ActiPix® UV area imaging technology in specific fields of use related to the characterization of complex fluids for applications in biopharmaceuticals, foods and personal care industrial sectors.

From Malvern Panalytical 20 Jul 2011

Two existing clinical stage clients expand development activities with Progenitor Cell Therapy

Progenitor Cell Therapy (PCT), an internationally recognized cell therapy services and development company, and a wholly-owned subsidiary of NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that two existing clinical stage biopharmaceutical corporate clients have chosen to expand their development activities with PCT.

18 Jul 2011

WebMD anticipates 15% increase in revenue for second quarter 2011

WebMD Health Corp., the leading source of health information, today announced preliminary financial results for the three months ended June 30, 2011 and updated financial guidance for 2011.

18 Jul 2011

FDA approves Shire's Lialda for maintenance of remission of ulcerative colitis

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis.

18 Jul 2011

Sofinnova Ventures leads $44 million Series B private equity financing for SARcode Bioscience

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners.

18 Jul 2011

SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load

SEEK, a privately owned biopharmaceutical company specializing in immunology, announces today that it has completed a Phase Ib/II clinical trial of its HIV-v vaccine which demonstrates a one log (approx 90 percent) difference in viral count in HIV-infected people compared with the placebo group, after just a single vaccine injection.

18 Jul 2011

Guizhou Provincial Health Department issues 'Revised Plan' for blood collection stations

China Biologic Products, Inc., a leading plasma-based biopharmaceutical company in China, today announced that the Guizhou Provincial Health Department has issued the revised "Plan for Guizhou Provincial Blood Collection Institutional Setting."

16 Jul 2011

Scientists identify new metabolic pathway for breast cancer

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, announced today a publication in the journal Nature that identifies dysregulated activity of the serine pathway as a novel metabolic target in certain breast cancers.

15 Jul 2011

CVS Caremark adds Access' MuGard to pharmacy benefit network

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.

15 Jul 2011

NeoStem to acquire Amorcyte

NeoStem, Inc., an international biopharmaceutical company, announced the signing of a definitive merger agreement whereby NeoStem will acquire Amorcyte, Inc., a development stage cell therapy company focusing on novel treatments for cardiovascular disease.

15 Jul 2011

Verastem raises $32 million to develop targeted cancer stem cell therapies

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced today that it has raised $32 million through a Series B financing. Proceeds from the financing will support ongoing research and development and will progress drug candidates into clinical development. The first candidate is projected to enter the clinic in 2012.

14 Jul 2011

Accelrys releases Discovery Studio software for biotherapeutics research

Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced a new release of the Discovery Studio life sciences modeling and simulation software.

14 Jul 2011

Viewpoints: Prominent Republicans against IPAB; docs defend health law; medical marijuana research

The IPAB has created "immediate uncertainty at hand," says Scott & White Healthcare in central Texas, for their 12 hospitals and more than 800 physicians. Many more organizations and associations have expressed similar concerns and urged me to do what I can to repeal this ill-conceived bureaucratic board. That's why I have introduced the Health Care Bureaucrats Elimination Act, and why I'm testifying Wednesday on the other side of the Capitol to build support in the House.

14 Jul 2011

Ipsen, Salk Institute renew Life Sciences Program

Ipsen and The Salk Institute for Biological Studies announced today that they are renewing the Ipsen Life Sciences Program at The Salk Institute.

12 Jul 2011

IGR, IPSEN sign 3 year medical oncology agreement

IPSEN, a global biopharmaceutical company represented by Claude Bertrand, Executive Vice President, R&D and Chief Scientific Officer, and Institut de cancérologie Gustave Roussy, a leading international cancer center represented by Professor Alexander Eggermont, General Director, today announced the signature of a partnership in the area of medical oncology to leverage the combined expertises of their respective R&D teams.

12 Jul 2011

Biopharmaceutical News and Research

Decision Resources announces acquisition of PharmaStrat

Mayo Clinic trial to evaluate folate receptor alpha-targeted breast/ovarian cancer vaccine

Galectin, University of Michigan enter collaboration to study role of Galectins in cardiovascular disease

Identification of third microRNA target triggers milestone payment from GSK to Regulus

PAREXEL completes 100th Asian ethnobridging study

Malvern and Paraytec enter into development and technology licensing agreement

Two existing clinical stage clients expand development activities with Progenitor Cell Therapy

WebMD anticipates 15% increase in revenue for second quarter 2011

FDA approves Shire's Lialda for maintenance of remission of ulcerative colitis

Sofinnova Ventures leads $44 million Series B private equity financing for SARcode Bioscience

SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load

Guizhou Provincial Health Department issues 'Revised Plan' for blood collection stations

Scientists identify new metabolic pathway for breast cancer

CVS Caremark adds Access' MuGard to pharmacy benefit network

NeoStem to acquire Amorcyte

Verastem raises $32 million to develop targeted cancer stem cell therapies

Accelrys releases Discovery Studio software for biotherapeutics research

Viewpoints: Prominent Republicans against IPAB; docs defend health law; medical marijuana research

Ipsen, Salk Institute renew Life Sciences Program

IGR, IPSEN sign 3 year medical oncology agreement

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News